The global Rare Hemophilia Factors Market is estimated to reach USD 336.3 million by 2025. The rare hemophilia factors industry is anticipated to rise at a healthy growth rate in the years to come. The increasing occurrence of several blood-related diseases such as myeloma, anemia, sickle cell anemia, and leukemia has led hematologists to pay heed to numerous discovery procedures. Hematologists are advising improved treatment procedures over precise diagnosis procedures.
In addition, to develop effective treatment methods, hematologists are significantly concentrating on the initial judgment of the numerous hematologist syndromes. The market is projected to grow at a significant CAGR of 5.1% in the upcoming period as the scope, product types, and applications are increasing across the globe.
The rare hemophilia factors market may be explored by type, treatment, and geography. Rare hemophilia factors industry may be explored by type as Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, and Factor XIII. Factor-VII deficiency sector is estimated to account for the highest market share in the forecast period. The share is anticipated to continue with its position throughout the forthcoming period. The development of the segment can be ascribed to the accessibility of treatment choices such as recombinant factor VIIa (rFVIIa), NoVo Seven (manufactured by Novo Nordisk, Denmark).
Rare hemophilia factors market may be explored by Treatment as Cryoprecipitate, Fresh Frozen Plasma, Factor Concentrates, and Others. The “Fresh frozen plasma” segment is estimated to account for the highest share in the forecast period. The segment is anticipated to continue with its position, increasing at the highest CAGR in the years to come. Fresh frozen plasma includes blood proteins and all clotting factors.
North America accounted for the major share of the global rare hemophilia factors market Size Analysis in 2016 and will continue to rule the roost in the forecast period. North America is followed by Asia-Pacific. Moreover, Asia-Pacific is anticipated to witness a peak development over the upcoming period due to the increasing population in Asian countries, increasing occurrence of autosomal recessive disorders due to consanguineous marriages in nations such as China, India, and Pakistan.
Some of the key players that fuel the growth of the rare hemophilia factors industry include Alexion Pharmaceuticals, Inc., Biogen Inc., Shire plc, Novo Nordisk A/S, CSL Behring LLC, Bayer Healthcare AG, Pfizer Inc., PRA Health Sciences, Amgen Inc, and Celgene Corporation. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures to boost the inorganic growth of the industry.
Rare Hemophilia Factors Type Outlook (Revenue, USD Million, 2014 - 2025)
• Factor I
• Factor II
• Factor V
• Factor VII
• Factor X
• Factor XI
• Factor XIII
Rare Hemophilia Factors Treatment Outlook (Revenue, USD Million, 2014 - 2025)
• Factor Concentrates
• Fresh Frozen Plasma
Rare Hemophilia Factors Regional Outlook (Revenue, USD Million, 2014 - 2025)
• North America
• the U.S.
• the U.K.
• the Asia Pacific
• Latin America
• the Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
Research Support Specialist, USA
FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...